戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tigen-specific fashion upon conjugation with maytansinoid.
2 that is specific for PSMA conjugated to drug maytansinoid 1 (DM1), a microtubule-depolymerizing compo
3  the maytansinoid antimicrotubule agent drug maytansinoid-1 directly to prostate-specific membrane an
4 gnificance, we report that a clinically used maytansinoid ADC, ado-trastuzumab emtansine (T-DM1), wit
5 ing, the therapeutic activity of trastuzumab maytansinoid ADCs can be further improved.
6 lusters required for the biosynthesis of the maytansinoid, ansamitocin, from a cosmid library of Acti
7 ument in favor of IMGN529, a novel anti-CD37 maytansinoid antibody-drug conjugate (ADC), elegantly sh
8 uses trastuzumab to specifically deliver the maytansinoid antimicrotubule agent DM1 to HER2-positive
9 s an immunoconjugate designed to deliver the maytansinoid antimicrotubule agent drug maytansinoid-1 d
10                                              Maytansinoids are potent antitumor agents found in plant
11 in and conjugates of potent tubulin poisons (maytansinoids auristatins and taxoids) are undergoing cl
12                              A series of new maytansinoids, bearing a disulfide or thiol substituent
13            Our results strongly suggest that maytansinoid-conjugated anti-PSCA monoclonal antibodies
14                                              Maytansinoid-conjugated antibodies caused complete regre
15 amined the metabolic fate in cells of huC242-maytansinoid conjugates containing either a disulfide li
16 ght into the mechanism of action of antibody-maytansinoid conjugates in general, and more specificall
17     Antiproliferative effects of trastuzumab-maytansinoid conjugates were evaluated on cultured norma
18 ing is required for the activity of antibody-maytansinoid conjugates, irrespective of the linker.
19 s to better define this process for antibody-maytansinoid conjugates.
20 l molecule-based immune checkpoint-targeting maytansinoid conjugates.
21  for the characterization of other ADCs with maytansinoid derivatives as payload.
22  vitro and in vivo antitumor activity of the maytansinoid DM1 (N(2')-deacetyl-N(2')-(3-mercapto-1-oxo
23 sistance, we conjugated the highly cytotoxic maytansinoid DM1 to antibodies via the maleimidyl-based
24 he chimeric human mAb to the tubulin-binding maytansinoid DM1 using a bioorthogonal chemical reaction
25 A) to a potent microtubule-inhibiting agent, maytansinoid DM1, via an intramolecular disulfide bond.
26 ug conjugate (ADC) named IgG78-DM1, in which maytansinoid (DM1) was linked to a fully human antibody
27           The antibody was conjugated to the maytansinoid, DM1, a potent antimicrotubule agent, via t
28 tor 2 (HER2) antibody, trastuzumab, with the maytansinoid, DM1, a potent microtubule-disrupting agent
29 -binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent.
30 al antibody linked to the tubulin-disrupting maytansinoid DM4, in a population of patients with FRalp
31 jugate of anti-mesothelin antibody linked to maytansinoid DM4, in patients with advanced, metastatic,
32           In contrast, therapy with the free maytansinoid drug (in the form of DM1-S-Me) proved not t
33 o yield metabolites consisting of the intact maytansinoid drug and linker attached to lysine.
34 ugates between monoclonal antibodies and the maytansinoid drug DM1 (MAb-DM1).
35                                          The maytansinoid drug DM1 is 100- to 1000-fold more cytotoxi
36 ped for detection and quantification of free maytansinoid drug in disulfide-linked conjugates between
37 ses of potent anti-tubulins, auristatins and maytansinoids, indiscriminately radiosensitize tumour ce
38 (epsilon)-SMCC-DM1 as the sole intracellular maytansinoid metabolite.
39 harmacokinetics, and toxicity of trastuzumab-maytansinoid (microtubule-depolymerizing agents) conjuga
40 so identified and characterized the released maytansinoid molecules from these conjugates, and measur
41                   HuN901 conjugated with the maytansinoid N(2')-deacetyl-N(2')-(3-mercapto-1-oxopropy
42 h the microtubule-formation inhibitor DM1 (a maytansinoid), or with the DNA alkylator DC1 (a CC1065 a
43 d trastuzumab or trastuzumab linked to other maytansinoids through disulfide linkers.
44               The targeted delivery of these maytansinoids, using monoclonal antibodies, resulted in
45                             Several of these maytansinoids were found to be even more potent in vitro